Regeneron antibody cocktail..
Regeneron Pharmaceuticals, Inc.
September 29, 2020 at 4:01 PM EDT
REGENERON'S REGN-COV2 ANTIBODY COCKTAIL REDUCED VIRAL LEVELS AND IMPROVED SYMPTOMS IN NON-HOSPITALIZED COVID-19 PATIENTS
TARRYTOWN, N.Y., Sept. 29, 2020 /PRNewswire/ –
https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and
'About REGN-COV2
REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.
To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population, as detailed in Science. Preclinical studies have shown that REGN-COV2 reduced the amount of virus and associated damage in the lungs of non-human primates.'
Regeneron Pharmaceuticals, Inc.
June 11, 2020 at 7:17 AM EDT
TWO SCIENCE PUBLICATIONS HIGHLIGHT POTENTIAL OF REGN-COV2 ANTI-VIRAL ANTIBODY COCKTAIL TO PROTECT AGAINST SARS-COV-2 ESCAPE MUTANTS
TARRYTOWN, N.Y., June 11, 2020 /PRNewswire/ –
https://investor.regeneron.com/news-releases/news-release-details/two-science-publications-highlight-potential-regn-cov2-anti
'The first paper entitled "Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail" describes Regeneron's parallel efforts using both humanized VelocImmune® mice and blood samples from recovered COVID-19 patients to generate a large and diverse collection of antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on the virus cell surface binds to the host cell and is required for infectivity. By blocking its interaction with the host cell, antibodies are able to neutralize the virus and block infection. Regeneron scientists selected pairs of highly potent individual antibodies that simultaneously and non-competitively bind to the RBD. Regeneron pursues a multi-antibody cocktail approach for infectious diseases in order to decrease the potential for the virus to escape.'
'the second paper, entitled "Antibody Cocktail to SARS-Cov-2 Spike Protein Prevents Rapid Mutational Escape Seen with Individual Antibodies," which further defines the protective value of the multiple-antibody approach against SARS-CoV-2 specifically. This research for the first time demonstrates that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserved regions on the spike protein. However, escape mutants could not be efficiently generated following exposure to the REGN-COV2 cocktail since it utilizes two antibodies that can simultaneously bind to distinct regions of the RBD.'
1.
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
https://science.sciencemag.org/content/369/6506/1010
2.
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
https://science.sciencemag.org/content/369/6506/1014